共 15 条
[2]
CRISPR/Cas9-mediated targeted chromosome elimination[J] . Erwei Zuo,Xiaona Huo,Xuan Yao,Xinde Hu,Yidi Sun,Jianhang Yin,Bingbing He,Xing Wang,Linyu Shi,Jie Ping,Yu Wei,Wenqin Ying,Wei Wei,Wenjia Liu,Cheng Tang,Yixue Li,Jiazhi Hu,Hui Yang.Genome Biology . 2017 (1)
[3]
Pharmacotherapeutic Considerations for Individuals with Down Syndrome
[J].
PHARMACOTHERAPY,
2017, 37 (02)
:214-220
[4]
Chromosome therapy: Potential strategies for the correction of severe chromosome aberrations[J] . Kathleen Plona,Taehyun Kim,Katherine Halloran,Anthony Wynshaw‐Boris.American Journal of Medical Genetics Part C: Semi . 2016 (4)
[6]
Hypermethylated ERG as a cell-free fetal DNA biomarker for non-invasive prenatal testing of Down syndrome[J] . Xi Chen,Likuan Xiong,Ting Zeng,Kelin Xiao,Yanping Huang,Hui Guo,Jinghui Ren.Clinica Chimica Acta . 2015
[8]
Pregnancy associated plasma protein-A2: A novel biomarker for down syndrome[J] . S. Munnangi,S.J. Gross,R. Madankumar,G. Salcedo,S.E. Reznik.Placenta . 2014 (11)
[9]
Chromosome therapy[J] . Taehyun Kim,Marina Bershteyn,Anthony Wynshaw-Boris.Nucleus . 2014 (5)
[10]
Non-invasive prenatal screening for trisomy 21: What women want and are willing to pay[J] . E.J. (Joanne) Verweij,Dick Oepkes,Marieke de Vries,M.E. (Elske) van den Akker,Eline S. van den Akker,Marjon A. de Boer.Patient Education and Counseling . 2013 (3)